<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03636373</url>
  </required_header>
  <id_info>
    <org_study_id>Pro2018000562</org_study_id>
    <nct_id>NCT03636373</nct_id>
  </id_info>
  <brief_title>Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout</brief_title>
  <official_title>Investigator-Initiated, Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to investigate the safety and efficacy of etanercept&#xD;
      (Enbrel™; Amgen) for the treatment of an acute gout attack will be non-inferior to&#xD;
      triamcinolone acetonide an FDA approved drug to treat acute gout attacks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Temporarily paused due to COVID 19 and expected to resume&#xD;
  </why_stopped>
  <start_date type="Anticipated">June 15, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be administered a single dose of etanercept 50 mg subcutaneously (SC), at the onset of an acute gout attack, or a single dose of triamcinolone acetonide 40 mg intramuscularly (IM)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Triple</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Joint pain intensity in the most affected joint</measure>
    <time_frame>72 hours</time_frame>
    <description>Pain intensity in the most affected baseline joint measured by the numeric 0-10 pain scale at 72 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Joint pain on numeric pain scale</measure>
    <time_frame>Days 4, 7, and 14</time_frame>
    <description>Patient's assessment of joint pain intensity in the most affected baseline joint on a 0-10 pain scale, at Baseline and post-dose Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's assessment of response to treatment</measure>
    <time_frame>Day 4, 7 and 14</time_frame>
    <description>Patient's global assessment of response to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's assessment of response to treatment</measure>
    <time_frame>Post-dose days 4, 7 and 14</time_frame>
    <description>Physician's global assessment of response to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication</measure>
    <time_frame>Days 4, 7, 14</time_frame>
    <description>Compare the use of rescue medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Etanercept</measure>
    <time_frame>During study</time_frame>
    <description>Safety and tolerability as assessed by subjects with adverse events and serious adverse events from baseline through Visit 5 safety follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gout Attack</condition>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered etanercept 50 mg subcutaneously and a placebo intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone acetonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be administered triamcinolone acetonide 40 mg intramuscularly and a placebo subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2</description>
    <arm_group_label>Etanercept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide</intervention_name>
    <description>Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2</description>
    <arm_group_label>Triamcinolone acetonide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients age ≥18 to ≤85 year&#xD;
&#xD;
          2. History of established gout&#xD;
&#xD;
          3. Onset of current acute gout attack within 4 days prior to randomization with: presence&#xD;
             of any warm joint, swollen joint, pain score at rest ≥5 on the 0-10 pain scale,&#xD;
             patient self-report of acute gout attack&#xD;
&#xD;
          4. Baseline pain intensity ≥5 on a 0-10 pain scale;&#xD;
&#xD;
          5. Tender (≥1 on a 0-4-point Likert scale) and swollen (≥1 on a 0-4-point Likert scale)&#xD;
             index joint;&#xD;
&#xD;
          6. If on urate-lowering therapy, a stable dose and regimen for at least 2 weeks prior to&#xD;
             randomization, and expectance to remain on a stable dose and regimen for the duration&#xD;
             of the double-blind treatment period, and;&#xD;
&#xD;
          7. Body mass index (BMI) ≤45 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of intra-articular or IM corticosteroids within 14 days prior to screening;&#xD;
&#xD;
          2. Use of an IL-1 inhibitor, TNF inhibitor or other biologic or investigational drug&#xD;
             within 30 days prior to screening;&#xD;
&#xD;
          3. History of a drug allergy to either study drug;&#xD;
&#xD;
          4. Diagnosis or history of:&#xD;
&#xD;
               1. rheumatoid arthritis (RA);&#xD;
&#xD;
               2. infectious/septic or other inflammatory arthritis;&#xD;
&#xD;
               3. alcoholic hepatitis or nonalcoholic steatohepatitis;&#xD;
&#xD;
               4. immunodeficiency syndromes, including Human Immunodeficiency Virus (HIV)&#xD;
                  infection;&#xD;
&#xD;
               5. Stage IIIb, IV, or V chronic kidney disease;&#xD;
&#xD;
               6. idiopathic thrombocytopenic purpura;&#xD;
&#xD;
               7. active, severe chronic pulmonary disease (eg, requiring oxygen therapy);&#xD;
&#xD;
               8. uncontrolled hypertension (≥ 200/105 mmHg);&#xD;
&#xD;
               9. symptomatic (New York Heart Association Class II, III, or IV) congestive heart&#xD;
                  failure;&#xD;
&#xD;
              10. uncontrolled diabetes Type I or II (recent blood glucose &gt; 300 mg/dL);&#xD;
&#xD;
              11. myocardial infarction, unstable cardiac arrhythmias or unstable symptomatic&#xD;
                  coronary ischemia, within the past 12 months before randomization;&#xD;
&#xD;
              12. history of malignancy of any organ system within the past 5 years;&#xD;
&#xD;
              13. multiple sclerosis or any other demyelinating disease, or;&#xD;
&#xD;
              14. major chronic inflammatory disease or connective tissue disease other than RA or&#xD;
                  psoriatic arthritis (PsA), including but not limited to fibromyalgia or systemic&#xD;
                  lupus erythematosus (with the exception of secondary Sjögrens syndrome, etc.);&#xD;
&#xD;
          5. Contraindication to IM injection;&#xD;
&#xD;
          6. Donation or loss of ≥400 milliliters (mL) of blood in the 8 weeks before dosing;&#xD;
&#xD;
          7. Any live vaccination in the 3 months before the start of the study;&#xD;
&#xD;
          8. Active infection (including chronic or localized infections) for which antiinfectives&#xD;
             were indicated within 4 weeks before screening;&#xD;
&#xD;
          9. Any serious infection, defined as requiring hospitalization or intravenous&#xD;
             anti-infectives, within 8 weeks before first dose of investigational product;&#xD;
&#xD;
         10. Prosthetic joint infection within 5 years of screening, or native joint infection&#xD;
             within 1 year of screening;&#xD;
&#xD;
         11. Known alcohol addiction or dependency, daily alcohol use, or current substance use or&#xD;
             abuse;&#xD;
&#xD;
         12. Positive medical history for hepatitis B or C (subjects with a history of hepatitis B&#xD;
             vaccination without history of hepatitis B infection are allowed to enroll);&#xD;
&#xD;
         13. History of active tuberculosis;&#xD;
&#xD;
         14. Positive test for tuberculosis during screening, defined as positive Purified Protein&#xD;
             Derivative (PPD) skin test (≥5 mm induration at 48-72 hours after test is placed), or&#xD;
             positive Quantiferon test;&#xD;
&#xD;
         15. Pregnant or nursing (lactating) women&#xD;
&#xD;
         16. Female patients who are physiologically capable of becoming pregnant must use an&#xD;
             acceptable method of contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naomi Schlesinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Robert Wood Johnson Medical School/ Rutgers RWJMS Gout center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rutgers, Robert Wood Johnson Medical School, Clinical Research Center</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Naomi Schlesinger, MD, Professor of Medicine</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

